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Cells regularly synthesize new proteins to replace old and abnormal proteins for
normal cellular functions. Two significant protein quality control pathways inside the
cellular milieu are ubiquitin proteasome system (UPS) and autophagy. Autophagy is
known for bulk clearance of cytoplasmic aggregated proteins, whereas the specificity
of protein degradation by UPS comes from E3 ubiquitin ligases. Few E3 ubiquitin
ligases, like C-terminus of Hsc70-interacting protein (CHIP) not only take part in
protein quality control pathways, but also plays a key regulatory role in other cellular
processes like signaling, development, DNA damage repair, immunity and aging.
Abbreviations: AhR, aryl hydrocarbon receptor; AIF, apoptosis-inducing factor; Akt, AKR/J thyoma protein kinase;
ALS, amyotrophic lateral sclerosis; APC, anaphase promoting complex; APP, amyloid precursor protein; AR, androgen
receptor; ASK1, apoptosis signal-regulating kinase 1; AXL, receptor tyrosine kinase AXL; BAG, B-cell lymphoma-2
(BCL-2)-associated athanogene; BCR- ABL, break point cluster abelson murine leukemia viral oncogene; BMP, bone
morphogenetic protein; CAD, caspase recruitment domain; CAP, chaperone-assisted proteasomal degradation; CARMA1,
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GCH1, guanosine-5′-triphosphate cyclohydrolase 1; GHR, growth hormone receptor; GR, glucocorticoid receptor; GUCY,
guanylate cyclase; HECT, homologous to the E6-AP carboxyl terminus; HIF-1α, hypoxia-inducible factor-1 alpha; Hip,
Hsc70 interacting protein; Hop, Hsp70/Hsp90 organizing protein; HSF1, heat shock factor 1; HspB8, heat shock protein B8;
hTERT, human telomerase reverse transcriptase; ICER, inducible cyclic activated protein kinase (AMP) early repressor;
IRE1, inositol requiring enzyme 1; IRF1, interferon regulatory factor 1; JNK, c-Jun N-terminal kinase; LC3, microtubule-
associated protein 1A/1B-light chain 3; LKB1, liver kinase B 1; LRRK2, leucine-rich repeat kinase 2; MAPK, mitogen-
activated protein kinase; MDM2, mouse double minute 2 homolog; MEKK2, MAPK/ERK kinase kinase 2; MIF, migration
inhibitory factor; MKKS, McKusick-Kaufman syndrome protein; MLK3, mixed-lineage kinase 3; nAChRs, neuronal nicotinic
acetylcholine receptors; NFkB, nuclear factor κB; NPM-ALK, nucleophosmin-anaplastic lymphoma kinase; Pael-R, Parkin-
Associated Endothelin Receptor-Like Receptor; PI3K, phosphoinositide 3-kinase; PKCζ, protein kinase C ζ; PRMT5, protein
arginine methyltransferase 5; PTEN, phosphatase and tensin homolog deleted on chromosome TEN; PTK6, protein tyrosine
kinase 6; Raf1, rapidly accelerated fibrosarcoma 1; RING, Really Interesting New Gene; Ron, recepteurd’originenantais
kinase; Runx1, runt-related transcription factor 1; SENP3, SUMO/sentrin protease 3; SEREX, serologic identification by
recombinant expression cloning; SGK1, serum and glucocorticoid-regulated kinase-1; SirT6, Sirtuin6; Smads, Sma-mother
against decapentaplegic; SOD1, superoxide dismutase1; Src, sarcoma viral oncogene homolog; SRC3, steroid receptor
coactivator-3; STUB1, STIP1 homology and U-Box containing protein 1; Tal1/Sc1, T-Cell acute lymphocytic leukemia 1;
TDP-43, TARDNA-binding protein 43; TPR, tetratricopeptide repeat; TRAF2, TNF receptor-associated factor 2; TRAT, T cell
receptor associated transmembrane adaptor 1; UFD2, ubiquitin fusion degradation 2; UPS, Ubiquitin Proteasome System;
XRCC1, X-ray repair cross-complementing group-1.
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CHIP targets misfolded proteins for their degradation through proteasome, as well
as autophagy; simultaneously, with the help of chaperones, it also regulates folding
attempts for misfolded proteins. The broad range of CHIP substrates and their
associations with multiple pathologies make it a key molecule to work upon and focus
for future therapeutic interventions. E3 ubiquitin ligase CHIP interacts and degrades
many protein inclusions formed in neurodegenerative diseases. The presence of CHIP
at various nodes of cellular protein-protein interaction network presents this molecule
as a potential candidate for further research. In this review, we have explored a wide
range of functionality of CHIP inside cells by a detailed presentation of its co-chaperone,
E3 and E4 enzyme like functions, with central focus on its protein quality control roles
in neurodegenerative diseases. We have also raised many unexplored but expected
fundamental questions regarding CHIP functions, which generate hopes for its future
applications in research, as well as drug discovery.
Keywords: E3 ubiquitin ligases, misfolded proteins, neurodegeneration, cell death, aging
INTRODUCTION
A nascent polypeptide chain achieves its native structure
with the help of folding machinery present inside the cells
that includes molecular chaperones and other associated
proteins. However, many of these proteins are not able
to fold properly and are needed to be cleared from the
cell by the cellular protein quality control system that
includes mainly ubiquitin proteasome system (UPS) and
autophagy. These two systems either work independently or
in collaboration with each other (Goldberg, 2003; Korolchuk
et al., 2010). Molecular chaperones are the supervisors of
newly synthesized polypeptides in the crowded cellular milieu.
The guidance of chaperones assists immature polypeptides
to acquire a functional macromolecular structure and move
towards appropriate cellular localization to perform pre-defined
functions (Ellis and Hemmingsen, 1989; Hartl, 1996). Two
well-studied chaperones are heat shock proteins, Hsp70 and
Hsp90. Heat shock proteins function as stress-induced proteins
to monitor changes in the molecular environment of the cell
(Nollen and Morimoto, 2002). The chaperones not only assist
new proteins in achieving the functional activity by proper
folding, but also play crucial roles in removal of aberrant
proteins, either by UPS or by autophagy pathway (Hartl et al.,
2011).
Chaperones participate in protein quality control processes
of the cell by forming complexes with E3 ubiquitin ligases,
ubiquitin molecules, various accessory co-chaperones (Hsp40,
BAG-1, BAG-3, etc.) and other proteins to tag misfolded or
improperly folded proteins for their removal from the cells
(Edkins, 2015). UPS involves ubiquitin-dependent degradation
of various misfolded proteins (Ciechanover, 1994; Hochstrasser,
1996). UPS consists of three enzymes E1 ubiquitin activating
enzyme, E2 ubiquitin conjugating enzymes and E3 ubiquitin
ligases. Other than these enzymes a small 76 amino acid
long ubiquitin protein, and 26S proteasome, the proteolytic
machinery of the cell with different types of protease activities,
are other major components of the UPS (Hershko, 1998). As
shown in Figure 1A, ubiquitination of a particular protein,
with the help of successive activities of E1, E2 and E3 enzymes
generates a degradation signal onto a protein, for its translocation
to the 26S proteasome interior, where the catalytic sites of
proteasome cleave polypeptide into smaller oligopeptides. The
specificity in the functioning of UPS comes from E3 ubiquitin
ligase enzymes, which recognizemisfolded proteins and continue
their elimination through catalytic activities of 26S proteasome
(Pickart, 2001).
Autophagy is another widely explored pathway that
helps in clearance of the cytoplasmic bulk of misfolded
proteins, by using lysosomal proteolysis (Seglen and Bohley,
1992). The cytoplasmic bulk includes aggregates, oligomers,
protein complexes, misfolded soluble proteins and sometimes
cellular organelles. Autophagic degradation begins with the
formation of the double-layered membrane, the phagophore,
that is designated as autophagosome when wrapped around
autophagic substrates. The tag of autophagosomal markers,
like p62 helps in the transportation of autophagosome
to lysosome for final degradation by lysosomal hydrolases
(Korolchuk et al., 2010). Chaperone-assisted selective autophagy
(CASA) and chaperone-mediated autophagy (CMA) are
examples of two types of autophagy, where chaperones are
involved in protein degradation, using this lysosomal pathway
(Kaushik and Cuervo, 2012). Chaperone-assisted proteasomal
degradation (CAP) elucidates another mechanism where
chaperones steer misfolded proteins towards the ubiquitin-
mediated proteasomal degradation (Kettern et al., 2010).
Chaperones are also responsible for the crosstalk between
these two pathways of protein degradation (Park and Cuervo,
2013).
C-terminus of Hsc70-interacting protein (CHIP) is
profoundly involved in most of the above-described quality
control pathways (Kettern et al., 2010). Previously, we have
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FIGURE 1 | Structural aspects of C-terminus of Hsc70-interacting protein (CHIP) and multiple sequence analysis of its domains. (A) Schematic
representation of the ubiquitin proteasome system (UPS) shows an ATP-dependent ubiquitin activation by E1 ubiquitin activating the enzyme, followed by
attachment of ubiquitin to E2 conjugating enzymes and later targeting misfolded proteins by specific E3 ubiquitin ligase enzymes for degradation by 26S proteasome
complex. (B) Human STIP1 Homology And U-Box Containing Gene 1 (STUB1) gene codes for E3 ubiquitin ligase CHIP; mRNA contains seven exons and six introns.
The mRNA synthesizes a 303 amino acid long protein, which contains three tetratricopeptide repeat (TPR) domains at its N-terminal and one U-box domain at its
C-terminals. A structural comparison of U-box domain with RING finger domain has been done to illustrate the respective arrangements of α-helices and β-sheets.
(C) Sequence alignment of CHIP with other co-chaperones, showing evolutionarily conserved TPR domains. (D) U-box domains of CHIP and different E3 ubiquitin
ligases have been aligned to elucidate their conserved region. Clustal Omega and Jalview were used for alignment and visualization respectively, with default coloring
schemes (Clamp et al., 2004; Sievers et al., 2011). Asterisk (∗) shows absolute conservation of amino acids, whereas score 0–9 followed by plus sign shows the
levels of amino acid conservation.
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shown various cellular strategies embraced by E3 ubiquitin
ligases in the removal of aberrant cellular proteins. Few E3
ubiquitin ligases like CHIP, cullin5, E6-AP, etc. function
in association with various chaperones like Hsp70, Hsp90,
etc. to maintain the quality of cellular proteins (Chhangani
et al., 2013). CHIP is one of the most extensively studied E3
ubiquitin ligase associated with chaperones (Murata et al.,
2001). E3 ubiquitin ligase activity of CHIP is because of its
evolutionarily conserved U-box domain, which is a modified
form of the Really Interesting New Gene (RING) domain
which also contains a metal chelating region (Hatakeyama
et al., 2001; Jiang et al., 2001). Cytoplasmic 35 kDa protein
CHIP was firstly recognized as a chaperone interacting protein
because of its tetratricopeptide repeat containing (TPR) domain,
which is similar to Hsp70-Hsp90 organizing protein (Hop)
and Hsc70 interacting protein (Hip; Ballinger et al., 1999).
Negative regulation of a substrate binding cycle of Hsc70-Hsp70
by CHIP reveals its dual role as co-chaperone as well as E3
ubiquitin ligase for protein quality control in cells (Connell et al.,
2001). CHIP has also been shown as a connecting link between
chaperones and proteasome system (McDonough and Patterson,
2003).
The involvement of CHIP in various physiological functions
defines its worth in the maintenance of cellular homeostasis;
earlier findings have described its roles in a number of pathways
and diseases (Paul and Ghosh, 2015). However, its exceptional
significance was found in an array of neurodegenerative
disorders with greater extent (Dickey et al., 2007). Another
potential reason of extensive research on CHIP is its association
with a wide range of diseases, such as cardiac disorders,
muscular disorders and different types of cancers (Adachi
et al., 2007; Willis et al., 2008; Cao et al., 2016). In this
review, we first describe structural aspects and involvement
of CHIP in various quality control pathways, and then
we elaborate its liaison in various diseases, with a special
focus on neurodegeneration and associated disorders. Loss of
neurons is more crucial than the loss of any other cell in
the body, as the possibility of recovery or replacement is
negligible in this case (Currais et al., 2009). Understanding
and analyzing available data about molecules like CHIP, that
are directly linked to multiple neurodegenerative diseases, will
provide hope for the development of preventive measures
for these pathologies. We, here, try to compile a detailed
and descriptive analysis of CHIP and its association with
neurodegenerative disorders, to focus on its wide scope in future
drug discovery.
JOURNEY OF CHIP: GENE TO PROTEIN
The CHIP protein in humans is encoded by STIP1 Homology
and U-Box Containing gene 1 (STUB1), with the cytogenetic
band at location p13.3 on chromosome number 16. The pre-
mRNA consists of seven exons and six introns within 2760 base
pairs of the CHIP/STUB1 gene. As represented in Figure 1B,
human CHIP protein is of 303 amino acids in length (Ballinger
et al., 1999; Shi et al., 2013). The first identification of CHIP
antigen was done in chronic lymphocytic leukemia patients,
using serologic identification by recombinant expression cloning
(SEREX) method (Krackhardt et al., 2002). The two isoforms
produced by alternate splicing are of 303 and 231 amino
acid long sequences having NCBI accession: NP_005852.2 and
NP_001280126.1 respectively, but no experimental confirmation
for the second isoform is available.
Structural Overview of CHIP Domains
Interaction of CHIP with heat shock proteins occurs because of
its TPR domain; this interaction of CHIP with C-terminus of
Hsc70 or Hsp70 does not have any interference in its binding
with misfolded proteins. Apart from TPR domain, its adjacent
positively charged region is also significantly responsible for this
interaction (Ballinger et al., 1999; McDonough and Patterson,
2003). Located at N-terminal of CHIP, this TPR domain
consists of three pairs of anti-parallel α-helices and elongated
seventh helix with packed N-terminus against its third helical
pair (Zhang et al., 2005). TPR domains are structurally
conserved among many other co-chaperones, which also have
a tendency to bind with Hsp70 and Hsp90 (McDonough and
Patterson, 2003). In a multiple sequence alignment analysis,
which is presented in Figure 1C, conserved nature of this
domain in CHIP and other co-chaperones are observed, giving
an indication of how the interaction of CHIP occurs with
chaperones and how this is directly associated with many other
co-chaperones.
STUB1/CHIP is a member of U-box-containing E3 ubiquitin
ligases family, which is also responsible for conferring it an
E4 enzyme-like activity (Jiang et al., 2001). The conserved ∼70
amino acids long U-box domain is found from yeasts to humans,
in various proteins (Hatakeyama et al., 2001). Previously, only
two families of E3 ubiquitin ligases, Homologous to the E6-AP
Carboxyl Terminus (HECT) and RING were well characterized
(Passmore and Barford, 2004; Metzger et al., 2012). But in last
two decades, many U-box containing proteins were identified
for their function in polyubiquitination (Aravind and Koonin,
2000; Ohi et al., 2003). They were therefore established as a
new family of E3 ubiquitin ligases which are also involved
in protein quality control functions (Cyr et al., 2002). The
U-box domain was first identified as multiubiquitin chain
forming domain in a yeast ubiquitin fusion degradation 2
(UFD2) protein (Koegl et al., 1999). Later, it was found that all
mammalian U-box proteins interact with chaperones, as in the
case of CHIP (Hatakeyama et al., 2004). Figure 1D compares
conserved regions of CHIP U-box domain with other U-box
containing E3 ubiquitin ligases obtained from multiple sequence
alignment.
Post-Translational Modifications of CHIP
Polypeptide
Ubiquitination is one of the ways to regulate CHIP activity.
Ube2W, an E2 ubiquitin conjugating enzyme, ubiquitylates
CHIP at N-terminus instead of any of its lysine residues,
as observed in the mass spectrometry data. This is one
type of protein modification that increases its activity of
ubiquitination of substrates (Tatham et al., 2013). A similar
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type of modification has been observed in the case of CHIP-
UbcH5A complex, which shows unconventional ubiquitination
by attaching polyubiquitin chain on CHIP, lacking specificity
for any of the seven lysine residues of ubiquitin (Windheim
et al., 2008). Another post-translational modification in CHIP
polypeptide is phosphorylation at two serine residues Ser19 and
Ser23 and also the presence of one auto-ubiquitination site
Lys22 (Graf et al., 2010). Interaction of CHIP with laforin-malin
complex promotes the translocation of CHIP from the cytoplasm
to the nucleus upon heat shock (Sengupta et al., 2011). These
examples of different types of modifications of CHIP sheds some
light on importance of this protein in cellular interactions and
also describes various ways, by which cell can precisely modify
its major proteins to effectively deliver their crucial functions.
Pathogenic Mutations of CHIP Associated
with Disorders
Mutation in STUB1 gene is one of the genetic causes of
the Gordon Holmes syndrome, an autosomal recessive
type of hereditary cerebellar ataxia in association with
hypogonadotropic hypogonadism (Ronnebaum et al., 2014;
Shi et al., 2014). Patients with mutations in this gene shows
similar neurological phenotypes, as shown by patients with a
mutation in two other genes associated with this syndrome
RNF216 andOTUD1 (Shi et al., 2013; de Roux et al., 2016). SCA3
mice, a disease model of Machado-Joseph disease, also showed
decreased levels of CHIP. This could probably be because of an
increase in affinity of ataxin-3 for CHIP, which results in such
decrease in CHIP levels throughout the brain (Scaglione et al.,
2011). Another study showed that mutation in STUB1 affects
its E3 ubiquitin ligase activity and prevents hypoxia inducible
factor-1 A (HIF1A) degradation by CMA (Ferreira et al., 2013).
A critical brain disease, intracranial aneurysm (IA), also involves
STUB1mutation that contributes to vascular remodeling, related
to the development of this disorder (Su et al., 2013). Study of
IL-4R signaling regulation by STUB1 reveals that its mutation
is linked with lung inflammation having hypersecretion of
the mucus and elevated level of serum IgE (Wei et al., 2014).
These mutations establish the eminent participation of this E3
ubiquitin ligase protein in many pivotal metabolic pathways and
developmental stages.
FUNCTIONAL PLASTICITY OF CHIP
Till date, more than 600 E3 ubiquitin ligases of different
domains, properties and activities have been identified, and
search is still on (Li W. et al., 2008). CHIP is important because
of its functional relevance in overall working and regulation
of the cell proteins. CHIP orchestrates regulation of cellular
proteins from folding to degradation by various mechanisms,
including a coordinated function with molecular chaperones
to refold the unfolded protein species, as well as a well-
directed degradation of those, which are beyond the refolding
range, via proteasome or autophagy. So, to accomplish such
a wide range of responsibilities, it should be a multifaceted
molecule (Connell et al., 2001). To perform this task, CHIP
has evolved various ways to ubiquitinate its substrates by
interaction with different E2 conjugating enzymes that form
a variety of signals, according to which it decides the fate
of substrates. E2s are the family of enzymes, having highly
conserved ubiquitin conjugating domain. These enzymes, in
combination with E3s, play an important role in determining
the fate of substrate proteins, by selecting a lysine residue, on
which ubiquitin moiety must be added. NMR studies provide
evidence that E2 enzymes require a well conserved S-P-A
motif in loop seven, which is found in many E2 enzymes, to
recognize and bind with CHIP. The specificity that determines
the binding of UbcH5 and Ubc13-Uev1a, the E2 ubiquitin-
conjugating enzymes, with CHIP E3 ubiquitin ligase is their
S-P-A motif. It also interacts with Ube2e2, the class III E2
enzyme because of this conserved S-P-A motif, providing the
significance of this motif in such kind of interactions between
U-box containing E3 ligases and associated E2 enzymes (Xu et al.,
2008).
The mechanism of polyubiquitination by binding of Ubc13-
Uev1a and UbcH5 with CHIP differ from each other as Ubc13-
Uev1a association causes Lys63-linked polyubiquitination,
whereas ubiquitination with UbcH5 does not have any
specificity of a lysine residue and the polyubiquitin chain
remains linked to CHIP (Windheim et al., 2008). It has been
shown in another finding that interaction with UbcH5 causes
Lys48-linked ubiquitination and it leads to degradation of
proteins (Murata et al., 2003; Schulman and Chen, 2005). An in
vitro study has shown that CHIP, with the aid of UbcH5 and
UbcH6, can efficiently ubiquitinate interferon regulatory factor 1
(IRF1), giving an idea of its modulation, under stress conditions
(Narayan et al., 2011). Similarly, another study based on CHIP
U-box domain showed that eight E2’s (Ube2D1, Ube2D2,
Ube2D3, Ube2E1, Ube2E2, Ube2E3, Ube2N and Ube2W) can
specifically interact with this domain (Soss et al., 2011). As
evident from the above studies, CHIP interacts and cooperates
with different E2’s. However, the basis of interaction towards
a particular E2, thereby, producing different ubiquitin signals,
is highly complex and still much work is needed to be done to
understand this mechanism.
CHIP, as a Co-Chaperone
There are various studies that provide evidence that CHIP
tightly regulates chaperones. It not only assists in the
functioning of chaperones, but also promotes or inhibits
their co-chaperone modulated activities. One such example
is the antagonistic regulation of Hop activity, by binding
of CHIP to C-terminus of Hsp70 and Hsp90, using its
TPR domain. Hop generally promotes folding of proteins
in conjugation with Hsp70/90 complex, with the aid of
Hsp40, stimulated ATPase activity of Hsc70. But, CHIP
when binds with Hsp90 through its TPR chaperone adapter
domain, further recruits E2 enzymes, ubiquitinate substrate
proteins and marks them for proteasomal degradation
(Ballinger et al., 1999; Höhfeld et al., 2001). As shown
in Figure 2, CHIP competitively dissociates p23, another
Hsp90 associated co-chaperone, which promotes Hsp90-
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 October 2016 | Volume 9 | Article 93
Joshi et al. CHIP Suppresses Neurodegeneration and Aging
FIGURE 2 | Multifaceted CHIP, functions as E3 ubiquitin ligase and co-chaperone. The illustration represents E3 ubiquitin ligase activity of CHIP through
which, it targets major class of its client proteins, when they are bound to Hsp70-Hsp90 chaperone complex. It ubiquitinates these proteins to tag them for
proteasomal degradation. CHIP is also known for its co-chaperone like functioning. The figure also represents antagonistic effects of CHIP against co-chaperones
Hsp40 and p23. CHIP antagonizes Hsp40 by inhibiting its ATPase activity which helps Hsp70 to fold its substrates (McDonough and Patterson, 2003). Similarly,
CHIP binds with Hsp90, causing release of p23, resulting in ubiquitination and further degradation of substrate proteins, such as glucocorticoid receptors (GR) and
erythroblastic leukemia viral oncogene homolog 2 (ErbB2; Connell et al., 2001; Höhfeld et al., 2001; Xu et al., 2002; Theodoraki and Caplan, 2012).
substrate dissociation; whereas binding of CHIP stabilizes
the complex and further ubiquitinates substrate protein for
degradation. Similarly, CHIP can also regulate the functionality
of Hsp70 by antagonizing the effect of Hsp40 in helping
the Hsp70 associated polypeptides to fold. CHIP binding
inhibits substrate folding-refolding pathway directed by
Hsc70/Hsp70 chaperones (Höhfeld et al., 2001; McDonough
and Patterson, 2003). Binding of CHIP with chaperones has
been seen as a mechanism of modulation of the activities
of the major chaperones in combination with other well
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known co-chaperone proteins. Such kind of regulatory
roles of CHIP over molecular chaperones gives it an extra
advantage of regulating levels of various substrate proteins,
apart from its regular E3 ligase like functions in degradation of
proteins.
CHIP, as an E3 Ubiquitin Ligase
Similar to RING domain E3 ubiquitin ligases, which have a zinc
binding motif, U-box domain containing E3 ubiquitin ligases
use salt bridges and hydrogen bonds to stabilize their three-
dimensional structures and perform their functions (Aravind
and Koonin, 2000). The presence of U-box domain in CHIP
led scientists to identify its potential as an E3 ubiquitin
ligase enzyme (Hatakeyama et al., 2001). Till now, multiple
evidence have been established and identified a wide and diverse
array of substrates, which have been shown to be associated
with CHIP with or without chaperones (Dickey et al., 2007;
Faresse et al., 2010). These substrates then get ubiquitinated
and degraded by either proteasomal or lysosomal pathways,
depending upon their mode of ubiquitination, as described
in detail in the next section. Interestingly, CHIP not only
regulates numerous substrates, but also ubiquitinate chaperones,
like Hsp70 and Hsp90 for their proteasomal degradation.
As shown in Figure 2, major class of CHIP substrates are
Hsp70-Hsp90 bound proteins, which are later ubiquitinated
and degraded by E3 ligase activity of CHIP. Previously, it
has been observed that after the depletion of substrates, CHIP
may also ubiquitinate and degrade Hsp70 in a proteasome-
dependent manner (Murata et al., 2001; Qian et al., 2006; Dickey
et al., 2007; Kundrat and Regan, 2010).This versatile capability
of CHIP to ubiquitinate in an array of patterns makes this
protein unique with a master control over a large variety of
substrates.
E4 Like Activity of CHIP
Yeast protein UFD2 was first identified for its unique activity
of binding with the ubiquitinated substrates and extends its
ubiquitin chain in conjugation with other UPS components
to make those substrates eligible for proteasomal degradation
(Koegl et al., 1999). U-box proteins were not only identified as the
third family of E3 ubiquitin ligases after HECT and RING finger
families, but also reflect their activity as E4 enzymes (Hatakeyama
et al., 2001). Among various E3 ubiquitin ligase enzymes, CHIP
was the first to be identified for its E4 activity, in association
with Parkin for Parkin-Associated Endothelin Receptor-Like
Receptor (Pael-R) degradation (Imai et al., 2002). This activity
makes it capable of adding further ubiquitin molecules, to form
a polyubiquitin chain. It also shows the collaborative ability
of CHIP with other E3 ubiquitin ligases in degradation of
substrates (Hoppe, 2005). CHIP enhances the efficiency of Parkin
to polyubiquitinate the Pael-R, resulting in its degradation via
the proteasome. CHIP associates with Hsp70 to make Parkin
free. As a result of this Parkin-Hsp70 dissociation, the activity
of E2 ubiquitin-conjugating enzymes increases, which enhances
the clearance of Pael-R, by Parkin from the cell (Imai et al.,
2002).
CHIP: A QUALITY CONTROLLER OF
CELLULAR PROTEOME
CHIP was first identified as a cytoplasmic protein, but in later
years, its functional role in the nucleus was also well established
(Ballinger et al., 1999). The localization studies of CHIP with
cystic-fibrosis transmembrane-conductance regulator (CFTR)
proposed its colocalization at the endoplasmic reticulum
membrane, to degrade it by the proteasome (Meacham et al.,
2001). The role of CHIP in the cytoplasmic quality control
system, later confirms its localization in the cytoplasm (Dai
et al., 2005). It was found that CHIP is partly localized in
the nucleus also, to perform functions like activation of heat
shock factor 1 (HSF1; Dai et al., 2003). The cytoplasmic CHIP
does not only take care of cytoplasmic proteins, but is also
involved in the ubiquitination and degradation of mitochondrial
proteins like leucine-rich repeat kinase 2 (LRRK2), a mutation
in which has largely been implicated in the onset of many cases
of familial Parkinson’s disease (Ding and Goldberg, 2009). CHIP
also ubiquitinates and degrades substrates like microtubule-
associated tau and β-amyloid precursor protein (β-APP), which
is localized in the Golgi complex (Kumar et al., 2007; Wang
and Mandelkow, 2012). Hence, enormous data presented by
various studies showed that function of CHIP is not confined
to any special cellular location, but, it plays significant roles
in the regulation of a variety of substrates, present in different
cellular locations and compartments. In Figure 3, we depict
the subcellular distribution of CHIP with few of its substrate
proteins to evince its cellular localization and functional potency.
As mentioned earlier, CHIP is involved in both pathways of
protein quality control: UPS and autophagy. The subsections
below describe and categorize substrates of CHIP, in accordance
with their degradative mechanisms. Most of its substrates have
found to be a proteasomal target, whereas some of them
are degraded through the lysosomal pathway. Interestingly,
few of them viz. inositol-requiring enzyme 1 (IRE1) are only
modified functionally, instead of being degraded by any of these
degradation pathways (Zhu et al., 2014).
Ubiquitin Proteasome System and CHIP
Harmony for Regulating Cellular Functions
Under Stress Conditions
To describe the involvement of CHIP in the UPS, it is important
to explain how different substrates are degraded by using
proteasomal machinery. The list of CHIP substrates begins
with heat shock protein Hsp70, which is not only functionally
regulated by CHIP, but is also degraded through the proteasomal
pathway by its E3 ubiquitin ligase activity (Qian et al., 2006).
CHIP efficiency of ubiquitination and proteasomal degradation
is higher for Hsp70 than Hsc70, although, these two are
highly similar in structure and homologous in sequence. There
is also a difference in the distribution of multiple ubiquitin
chain formation by CHIP among these two proteins (Soss
et al., 2015). Recently, studies on lens epithelial cells reported
that knockdown of CHIP affects the Hsp70 level during heat
stress, the concentration of Hsp70 in those cells is less, as
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FIGURE 3 | Represenation of subcellular localization of CHIP in various
cellular compartments. CHIP is widely distributed in most of the subcellular
compartments, including nucleus, cytoplasm, endoplasmic reticulum and
plasma membrane, in association with its substrates.
compared to negative control cells (Zhang et al., 2015). The
mouse model of ischemia/reperfusion-induced heart injury also
suggested that CHIP suppresses Hsp70 in the heart (Zhao
et al., 2012). Molecular chaperone Hsp70, in complex with
CHIP, leads to ubiquitination and elimination of various cellular
proteins, whereas Hsp90 and their client protein complexes
need to be destabilized first and then their ubiquitination
and removal takes place (Pratt et al., 2015). It was further
illustrated by a study, in which CHIP along with Hsp90
controls the stabilization and degradation of proteins such as
aryl hydrocarbon receptor (AhR) and SUMO/sentrin protease 3
(SENP3), which is involved in cellular response to mild oxidative
stress (Morales and Perdew, 2007; Yan et al., 2010). The optimal
levels of DNA polymerase β, DNA ligase III and X-ray repair
cross-complementing group-1 (XRCC1), the base excision repair
enzymes, are maintained by proteasomal degradation, through
CHIP (Parsons et al., 2008; Sobol, 2008). All these examples
show the cytoprotective nature of CHIP under various stress
conditions including heat shock, oxidative stress and DNA
damage etc.
Molecular Functions of CHIP in the Regulation of
Signaling Pathways and Cellular Proliferation
The proteins, which are regulated by CHIP, are shown to be
involved in many signaling pathways, and thus a dysregulation
may finally lead to a condition of cancer, neurodegeneration,
and other stress-related pathologies (Shang et al., 2014). The
signaling kinases like AKR/J thyoma protein kinase (Akt),
which is responsible for phosphorylation of tau and protein
tyrosine kinase 6 (PTK6), that is highly expressed in various
cancers are degraded by CHIP (Dickey et al., 2008; Kang et al.,
2012). Regulation of signaling by CHIP was also associated
with degradation of a typical protein kinase C ζ (PKCζ) and
sarcoma viral oncogene homolog (Src), involved in Toll-like
receptor-mediated immunity (Yang et al., 2011). Other kinases,
like nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)
and liver kinase B1 (LKB1) are degraded by E3 ubiquitin
ligase activity of CHIP (Bonvini et al., 2004; Gaude et al.,
2012). Nuclear factor-kB (NF-kB), TNF receptor-associated
factor 2 (TRAF2) and Caspase recruitment domain (CAD)
containing membrane-associated guanylate kinase (CARMA1),
key molecules participating in the regulation of the NF-kB
pathway is also regulated by ubiquitination and degradation
through CHIP (Jang et al., 2011; Wang et al., 2013a). The
studies also found the role of CHIP in maintaining the cellular
concentrations of proteins such as MAPK/ERK kinase kinase
2 (MEKK2) and mixed-linkage kinase (MLK3), which are
shown to be involved in important signaling pathways, like
extracellular signal-regulated kinase (ERK), mitogen-activated
protein kinase (MAPK) and c-Jun N-terminal kinase (JNK)
pathways, which regulate migration, invasion, proliferation and
apoptosis-like important cellular phenomenon (Maruyama et al.,
2010; Blessing et al., 2014). It maintains a steady level of kinases
such as dual leucine zipper-bearing kinase (DLK) and serum and
glucocorticoid regulated kinase-1 (SGK-1) in the cell, in complex
with Hsp70 (Belova et al., 2006; Daviau et al., 2006). Hsp90 client
protein, migration inhibitory factor (MIF), which is involved
in many signaling pathways, is also a well-known substrate of
CHIP (Schulz et al., 2012). Breakpoint cluster abelson murine
leukemia viral oncogene (BCR-ABL) and C-terminal binding
protein 2 (CtBP2) are other two proteins, added in this list
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of CHIP substrates (Tsukahara and Maru, 2010; Lee and Yoo,
2013).
The regulation of turnover of various receptors, that are
involved in signaling processes, by CHIP, is performed by
degrading proteins like glucocorticoid receptors (GR), estrogen
alpha receptor (ERα) and androgen receptor (AR), using UPS
(Wang and DeFranco, 2005; Zhang et al., 2011; Sarkar et al.,
2014). The E3 ubiquitin ligase function of CHIP maintains the
cellular level of recepteur d’origine nantais kinase (Ron) tyrosine
kinase receptor that binds with ligand macrophage-stimulating
protein to give the signal for proliferation and migration of cells
(Germano et al., 2006). Another protein of phosphoinositide
3-kinase (PI3K) signaling pathway, phosphatase and tensin
homolog deleted on chromosome TEN (PTEN) interacts with
the TPR domain of CHIP, by parts of its N-terminal domain
for ubiquitination and degradation (Ahmed et al., 2012). It also
regulates human telomerase reverse transcriptase (hTERT) and
hence modulates telomerase activity in cancer cells (Lee et al.,
2010). A tumor suppressor gene, menin, mutation in which
causes multiple endocrine neoplasia type1, is rapidly degraded
after being ubiquitinated by CHIP (Yaguchi et al., 2004).
CHIP is also important for the regulation of many proteins
involved in the formation of tumors, known as proto-oncogenes,
for example cErbB2/Neu and c-Myc (Xu et al., 2002; Paul et al.,
2013). Receptor tyrosine kinase AXL, that binds to the growth
arrest-specific protein 6, regulates the progression of many
cancers, is also a substrate of CHIP (Krishnamoorthy et al., 2013).
Overexpression of CHIP maintains the critical cellular levels of
substrate proteins and inhibits their over-accumulation, such
as erythroblastic leukemia viral oncogene homolog 2 (ErbB2),
a member of the receptor tyrosine kinase family that control
normal cell proliferation, differentiation and migration. The
new emerging anti-cancer strategies, involving downregulation
of ErbB2, also focus on the CHIP-mediated degradation of
this protein in association with molecular chaperones (Zhou
et al., 2003). The mutant p53, another tumor-causing protein,
is a substrate of CHIP and chaperone complex (Esser et al.,
2005). Tumor cell migration regulating protein, profilin, is also
a notable substrate of CHIP (Choi et al., 2014). As apoptosis
signal-regulating kinase 1 (ASK1) contain TPR acceptor site,
it was found that CHIP, with its TPR domain binds with this
site to ubiquitinate and degrade it by the proteasome (Hwang
et al., 2005). A truncated form of a mitochondrial protein,
apoptosis inducing factor (tAIF) is ubiquitinated and degraded
by CHIP in Hsp70 dependent manner (Oh et al., 2011). A
recent study summarizes that this interaction is disrupted by
cyclin-dependent kinase (Cdk5), which phosphorylates CHIP at
Ser20 position. Even after this disruption, E3 ubiquitin ligase
activity of CHIP remains intact, but this modification causes
inhibition of tAIF proteasomal degradation and thus leads to the
death of neurons (Kim et al., 2016). Endonuclease G, another
mitochondrial protein, which induces apoptosis is ubiquitinated
and degraded by CHIP to protect cells from cell death, induced
by oxidative stress (Lee et al., 2013). Recently, it was also
found that protein arginine methyltransferase 5 (PRMT5), an
oncoprotein, expressing at high concentration in a number
of human cancers, is negatively regulated by CHIP, which
ubiquitinates and degrade PRMT5 via proteasomal degradation
(Zhang et al., 2016). These line of evidence showing a diverse
range of substrates, including signaling molecules, receptor
proteins, various kinases, a number of oncoproteins and tumor
suppressors make this protein a potential target, which, in
future, may be exploited for the development of anti-cancer
strategies.
Cellular Functions and Relations of CHIP Associated
with Other Crucial Molecular Physiological Partners
Enzymes are also in the list of CHIP substrates, such as Hsp90
linked guanylyl cyclate (GUCY) and neuronal enzymes like
neuronal nitric oxide synthase (nNOS; Peng et al., 2004; Xia
et al., 2007). GTP cyclohydrolase I degradation controlled by
CHIP, regulates pulmonary blood flow (Sun et al., 2011). Proteins
like cytochrome 450 isoform 3A4 (CYP3A4) and NAD(P)H:
quinone oxidoreductase 1 (NQO1), are also governed by CHIP
for their cellular levels (Tsvetkov et al., 2011; Wang et al.,
2012). The complex of CHIP/Hsp70 involves association of
many other co-chaperones such as Hsp40, BAG-1 and BAG-3.
These co-chaperones, especially BAG-1, facilitate the ubiquitin
tagging of the substrate proteins, like rapidly accelerated
fibrosarcoma 1 (Raf1), and mark them for 26S proteasomal
destruction. BAG-1 interacts with CHIP and helps in the transfer
of the substrate from Hsp70 to CHIP-mediated proteasomal
degradation (Demand et al., 2001). Hsp70 bound CHIP was
also observed to take part in balancing critical concentrations
of proteins, such as mutant keratins and hypoxia-inducible
factor-1α (HIF-1α), which is a transcription factor for proteins
which are up-regulated in response to low oxygen levels (Luo
et al., 2010; Löffek et al., 2010). Thus, CHIP also controls adaptive
responses of cells in low oxygen conditions. Other studies also
suggest the involvement of CHIP in regulating the levels of
other Hsp90 client proteins such as runt-related transcription
factor 1 (Runx1) and LRRK2, via UPS, a protein whose mutation
is linked to Parkinson’s disease (Ding and Goldberg, 2009; Shang
et al., 2009). Hsp90 inhibitor molecules are investigated as it
has shown to control important signaling pathways, which are
up-regulated in many diseases. Thus, controlling the substrate
accumulation of Hsp90 client proteins by overexpressing CHIP
can provide options for treatment of various pathologies (Pratt
et al., 2015). The roles of CHIP/Hsp70 in regulation and
selective removal of aggregated protein inclusions from the cell
in various neurodegenerative disorders cannot be neglected.
A detailed picture of its involvement in various neurological
disorders has been presented in the later section of this
review.
Other anomalies of the genetic disorders such as McKusick-
Kaufman syndrome (MKKS), includes removal of mutant
MKKS protein from the cell by CHIP (Hirayama et al.,
2008). Translation-transcription regulators like eukaryotic
translation initiation factor 4E (eIF4E), a forkhead transcription
factor 1 (FoxO1) and histone deacetylase 6 (HDAC6) are also
ubiquitinated and degraded by proteasomal degradation via
CHIP interaction (Murata and Shimotohno, 2006; Li et al.,
2009; Cook et al., 2012). The E3 ubiquitin ligase CHIP is
also responsible for degradation of myocardin and katanin
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p60, hence, affects the differentiation in smooth muscle cells
and axonal growth, respectively (Xie et al., 2009; Yang et al.,
2013). The cardioprotective effect of CHIP is also because
of ubiquitination and degradation of inducible cyclic AMP
early repressor (ICER; Woo et al., 2010). Geldanamycin
(Hsp90 inhibitor) induces the degradation of estrogen
receptor alpha; CHIP not only increases this effect, but also
maintains the basal level of this receptor (Fan et al., 2005).
Sma-mother against decapentaplegic 1 (Smad1) and Smad4
are both coexpressed with the CHIP, and it was found that
Smad1 is preferentially degraded by the proteasome to block
bone morphogenetic proteins (BMP) signal transduction
(Li et al., 2007). In the case of interferon regulating factor
(IRF-1), trichostatin A treatment to cells causes enhanced
proteasomal degradation of IRF-1, by association with CHIP
(Gao et al., 2013). CHIP interaction with Hsp70 also controls
the critical level of neuronal nicotinic acetylcholine receptors
(nAChRs), which are involved in ganglionic transmission
and take part in smoking-related diseases (Teng et al., 2015).
Interaction of CHIP and Hsp70-Hsp90 chaperones largely
regulate a broad range of proteins, which are part of crucial
and important regulatory pathways. Regulatory control over
transcriptional and translational regulators designates CHIP
as a master controller of such a large network of proteins
which play critical roles in cellular metabolism, signaling and
proliferation.
CHIP-Mediated Autophagic Degradation
with the Help of Chaperones
Studies found that CHIP also plays a crucial role in maintaining
cellular level of many crucial proteins, by using the degradation
pathway of autophagy. It has been observed that CHIP/Hsp70
complex alleviates cells from the proteotoxic stress generated
by phosphorylated tau and mutant alpha-synuclein by using
both the systems of UPS and autophagy (Shin et al.,
2005; Wang and Mandelkow, 2012; Chesser et al., 2013).
Regulation of HIF1 by CHIP also involves oxygen dependent
proteasomal degradation and CMA (Luo et al., 2010; Ferreira
et al., 2013). Various other regulatory proteins and co-
chaperones are found to be associated with CHIP/Hsp70
complexes to reduce the proteotoxic load of the cell by using
autophagy, one such protein is growth hormone receptor
(GHR). Endocytosis of GHR is controlled by mainly two
types of modifications: phosphorylation and ubiquitination
by CHIP (Slotman et al., 2012; Sedek et al., 2014). A
coordination of CHIP and Hsp70 with molecules such as
BAG3, heat shock protein B8 (HspB8), directly control
client proteins using the machinery of autophagy, a process
known as CASA (Gamerdinger et al., 2011). Filamin, the
Z-disk maintaining protein is ubiquitinylated and degraded
by CHIP through CASA, so that actin can anchor properly
in striated muscles (Arndt et al., 2010). This mechanism
helps to maintain the integration of Z line and prevents
muscle weakness. Other studies suggest HspB8, BAG3 and
CHIP/Hsp70 complex effectively causes solubilization and thus
eliminates aggregates of mutant superoxide dismutase (SOD1)
FIGURE 4 | CHIP linked substrates in multiple cellular pathways and
abnormalities. CHIP substrates form a large group of proteins, implicated in
various important pathways and pathologies. Substrates are subdivided in
accordance with their association with cancer, neurodegeneration, signaling,
transcriptional regulation and development. Substrates have been put into
different boxes according to their degradative pathways. Yellow boxes
represent substrates, which are degraded by the proteasome, whereas brown
boxes represent the lysosomal degradation of CHIP substrates. Substrates
degraded by both proteasomal and lysosomal pathways are shown in the
green box. CHIP also ubiquitinates few of its substrates to functionally regulate
them instead of degrading, shown within the purple box.
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via the mechanism of autophagy. The autophagic flux of many
substrates in the cell is controlled by CHIP, as observed in
CHIP knockdown cells, where it regulates autophagic marker
proteins such as p62 and microtubule-associated protein 1A/1B-
light chain 3 (LC3; Guo et al., 2015). In Figure 4, we tried to
categorize the substrates of CHIP in accordance with pathways,
through which they are degraded and diseases, where these
proteins are involved. The ability of CHIP to degrade its
substrate proteins by multiple quality control pathways, make
its presence crucial for maintainance of cellular proteome
balance.
CHIP, A MOLECULE ASSOCIATED WITH
MULTIPLE NEURODEGENERATIVE
DISEASES
In the above section, we have described the role of CHIP in
quality control pathways, to maintain healthy cellular proteome.
It is evident from earlier research works, done by different groups
that most of the neurodegenerative diseases start developing
with few common pathological hallmarks (Jellinger, 2001).
Extra- or intracellular stresses and simultaneously, insufficient
functioning of various arms of cellular protein quality control
machinery may lead to structural modifications of some class of
cellular proteins, which may form misfolded oligomers. In many
cases, they start accumulating and forming inclusion bodies by
entangling with other functional cellular proteins, as evident
from microscopic analyses of different diseased brain tissues
(Irvine et al., 2008). Such kinds of toxic proteinaceous species
may lead to an array of neurological disorders e.g., Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, Amyotrophic
lateral sclerosis (ALS) and Lafora disease, etc. (Dickey et al.,
2007).
An interesting study in model organisms for identification
of common genetic modifiers of neurodegenerative diseases has
also shown the importance of CHIP (Chen et al., 2012). The gene
expression analysis data of SAMP8 mouse model of Alzheimer’s
disease by cDNA microarray technique, form a protein network
where CHIP represents an important node, which signifies its
influence on the disease (Cheng et al., 2013). In Figure 5, we
summarized the roles of CHIP in different neurodegenerative
disorders, where we have shown its association with the
misfolded proteins. Here, in this section of the review, we are
focusing on various roles attributed to E3 ubiquitin ligase like
activities of CHIP, in various neurodegenerative diseases.
Alzheimer’s Disease
The evidence points towards two major hypotheses as causative
factors for this severe neurodegenerative disease. The disease
begins with the formation of intracellular neurofibrillary tangles
FIGURE 5 | CHIP, a major E3 ubiquitin ligase of neurodegenerative disorders. CHIP ameliorates proteotoxicities in various proteinopathies. Studies have
shown that CHIP targets phosphorylated tau (Petrucelli et al., 2004; Qian et al., 2006; Koren et al., 2009), beta-amyloid (Kumar et al., 2012) in Alzheimer’s disease
(A), mutant superoxide dismutase (SOD1) aggregates (Urushitani et al., 2004) in Amyotrophic lateral sclerosis (ALS; B), Parkin-Associated Endothelin Receptor-Like
Receptor (Pael-R; Imai et al., 2002; McDonough and Patterson, 2003; Kumar et al., 2012), alpha-synuclein (Shin et al., 2005) in Parkinson’s disease (C) and
polyglutamine protein aggregates (Jana et al., 2005; Williams et al., 2009) in polyglutamine diseases (D), for their proteasomal degradation.
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of phosphorylated tau, a modified form of microtubule-
associated tau protein, as the major cause of Alzheimer’s
(Binder et al., 2005). In vivo studies clearly suggests that in
conjugation with UbcH5B, an E2 enzyme, CHIP-Hsp70 complex
polyubiquitylates phosphorylated form of tau in both K48 as
well as K63 linked manners and directs it for proteasomal
or autophagic degradation respectively (Petrucelli et al., 2004).
A second hypothesis, explaining the processing of amyloid
precursor protein (APP) by β-secretase, leads to accumulation of
amyloid beta (Aβ42) peptide fragments and then formation of
extra-cellular amyloid plaques, causing neuronal loss of function
or synaptic loss, and in later stages loss of neurons may lead
to death (Adalbert et al., 2007). Previous studies showed that
colocalization of CHIP with APP stabilizes its normal cellular
form; the same study also identified the involvement of CHIP in
conjugation withHsp70 andHsp90, in suppressing accumulation
of toxic Aβ42 peptide (Kumar et al., 2007). CHIP, therefore,
enhances overall cellular health, with increased rate of cell
survival (Shimura et al., 2004; Chesser et al., 2013). In Figure 5A,
we have shown the interaction of CHIP with both these toxic
proteins and their removal through the proteasomal pathway.
The phosphorylated tau and β-amyloid interact with CHIP.
This interaction further leads to ubiquitination and proteasomal
degradation of these proteins.
Amyotrophic Lateral Sclerosis
The other well-known neurodegenerative disorder, ALS, which
occurs due to mutations in SOD1, an antioxidant enzyme,
present on mitochondrial membranes and TAR DNA-binding
protein-43 (TDP-43), includes the roles of E3 ubiquitin
ligase CHIP. It mediates polyubiquitination of Hsp70/Hsc70,
which preferentially promotes degradation of SOD1 via 26S
proteasome, as shown in Figure 5B (Urushitani et al., 2004).
The overexpression of CHIP decreases cytotoxicity in cultured
human cells by reducing levels of mutant SOD1 together
with Hsp70/Hsc70 and Hsp90 (Choi and Lee, 2010). The
degradation of mutant SOD1 protein through autophagy is
carried out by Bag3/HspB8/Hsc70/CHIP complex that inserts
mutant protein into autophagosome (Crippa et al., 2010).
Another study describes increasing efficiency of Dorfin ligase
by the development of Dorfin-CHIP fusion protein for
degradation of mutant SOD1 protein (Ishigaki et al., 2007).
Further research on the involvement of CHIP in targeting
proteinaceous aggregates apart from SOD1, which is involved
in ALS, will contribute in identifying its potential roles in
ameliorating such kind of proteinopathies. TDP-43, cytoplasmic
inclusions are another hallmark of ALS. These aggregates of
TDP-43 interact with HDAC6, a substrate of CHIP/Hsp70.
The complex of HDAC6/CHIP/Hsp70, in normal conditions,
has the capability of deacetylating TDP-43, but they fail in
case of oxidative stimuli of high potency (Cohen et al.,
2015).
Parkinson’s Disease
Parkinson’s disease also involves the formation of various
proteotoxic inclusions inside the neurons, which may later result
in dementia or in extreme cases, the death of patients (Irvine
et al., 2008). The inclusions forming proteins of this disease are
Pael-R, α-synuclein and LRRK2. Pael-R, a G-protein coupled
receptor when accumulates in endoplasmic reticulum causes ER-
stress that leads to neuronal death by an unexplored mechanism
(Uversky and Fink, 2007; Ko et al., 2009). CHIP mediates
the dissociation of Hsp70 and Parkin, a known E3 ubiquitin
ligase of Pael-R, increases the ubiquitination of Pael-R and
subsequent degradation by UPS (Imai et al., 2002). Lewy bodies
are the cytoplasmic fibrillar aggregates of α-synuclein, known
as a pathological hallmark of Parkinson’s disease (Irvine et al.,
2008). Overexpression of CHIP in cell culture models showed its
colocalization with α-synuclein and Hsp70 and a reduction in
levels of α-synuclein associated inclusion bodies; it also caused
alteration in the morphology of these inclusions. The direct
interaction of CHIP and α-synuclein shows that clearance of α-
synuclein is not only carried out by proteasomal degradation, but
is also mediated by lysosomal pathways (Shin et al., 2005).
The oligomeric form of α-synuclein is preferentially
recognized by CHIP for degradation in the TPR domain
dependent and U-box independent manner (Tetzlaff et al.,
2008). In further studies, it was observed that the ubiquitination
of α-synuclein is regulated by BCL-2-associated athanogene5
(BAG5), it changes CHIP ability of reducing α-synuclein
oligomerization (Kalia et al., 2011). As shown in Figure 5C,
the above two described Parkinson’s linked protein Pael-R and
α-synuclein are degraded by CHIP-mediated ubiquitination. A
mutation in mitochondria-associated LRRK2 protein is found
to be involved in the onset of familial Parkinson’s disease have
also been reported as a substrate of CHIP (Ding and Goldberg,
2009; Ko et al., 2009). Another important role, this E3 plays,
is to maintain the mitochondrial integrity, its homeostasis and
overall functional health. CHIP knockout mice have impaired
mitochondria, showing defective mitophagy, malfunctioned
antioxidant defense and increased overall protein oxidation
with elevated levels of mitochondrial stress related proteins.
Increase in cellular protein and lipid oxidation are the major
causes of motor impairments; deficiency of CHIP generates
an oxidative insult which may lead to a decrease in neuronal
survival (Palubinsky et al., 2015).
Polyglutamine Diseases
Polyglutamine diseases like Huntington’s disease and
Spinocerebellar ataxia, also have involvement of CHIP substrate
proteins. Co-immunoprecipitation studies of CHIP and
polyglutamine-expanded proteins, huntingtin and ataxin-3
demonstrated CHIP’s role in polyglutamine diseases. E3
ubiquitin ligase CHIP along with Hsp70 ubiquitinates and
degrades polyglutamine aggregates of mutant huntingtin and
ataxin-3 (Jana et al., 2005; Dikshit and Jana, 2007), as depicted in
Figure 5D. In further studies, Huntington’s disease cell models,
primary neurons and zebra fish models show a reduction in
aggregates by the co-chaperone activity of CHIP. Also, CHIP
haploinsufficient mouse models showed an accelerated disease
phenotype giving an idea of the protective nature of CHIP
(Miller et al., 2005). Similarly, in fly-model of Spinocerebellar
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ataxia, with wild type and polyglutamine expanded ataxin-1,
CHIP was shown to reduce toxicity (Al-Ramahi et al., 2006).
CHIP ubiquitinates and degrades ataxin-1, decreases its
solubility, that causes the formation of insoluble aggregates,
which sequesters other misfolded proteins to provide cellular
protection (Choi et al., 2007). Mice with spinal and bulbar
muscular atrophy, a polyglutamine expansion disease, showed
improvement on overexpression of CHIP by reducing both
wild-type and poly Q-expanded androgenic receptor (Adachi
et al., 2007).
Lafora Disease
An autosomal recessive disorder involving neurodegeneration,
lafora disease, is a result of a mutation in either substrate
laforin or its E3 ubiquitin ligase malin (Gentry et al., 2005).
Lafora bodies, in this disease, are polyglucosan inclusions. CHIP
associates with malin-laforin complex and translocate the same
to the nucleus, resulting in the activation of cellular response
through upregulation of HSF1 (Sengupta et al., 2011). Malin,
which is involved in the degradation of laforin, itself, shows
the tendency of aggregate formation. Mutants of malin are not
stable like wild type malin, and form cytoplasmic and nuclear
aggregates; co-chaperone CHIP modulates stability of malin by
altering Hsp70 activity (Rao et al., 2010).
ROLES OF CHIP IN DEVELOPMENT AND
AGING PROCESSES
CHIP is an E3 ubiquitin ligase that has the capability to regulate
its substrate proteins, right from their folding, and up to the
stages of its degradation inside cells. It associates with different
chaperone complexes to monitor the folding processes, as well
as different protein degradation pathways, such as proteasome
and autophagy. It presents a direct connecting link between
these different arms of the protein quality control system:
molecular chaperones, UPS, and autophagy, as described in
the above sections. Apart from playing crucial roles in protein
structural modifications by its co-chaperone activity, CHIP
also takes part in the development of organisms. We, here,
try to emphasize few crucial roles of this E3 ubiquitin ligase
in development processes. CHIP substrate Runx2 is involved
in regulation of osteoblast differentiation. CHIP co-chaperone
domain TPR and C-terminus of Runx2 interacts with each other
and results in ubiquitination and degradation of Runx2, which
suppresses differentiation of preosteoblasts into osteoblasts. It
could probably be due to the repressed transcriptional activity
of Runx2. On the other hand, this inhibition of Runx2 by
CHIP results in increased rate of adipogenesis (Li X. et al.,
2008).
Another study showed the negative effect of the CHIP
knockout on total body weight of mice. The study points out its
role in the overall aging process of the organism. CHIP knockout
resulted in increased rate of atrophy, which was measured by
decreased size of the thymus, testis and skeletal muscles and the
cardiac hypertrophy also signifies the increased rate of aging.
Histological considerations were also taken into account, apart
from these anatomical studies. It was found that CHIP knockout
has a universal effect on the dermis, resulting in thinner dermis
layers as compared to control, as well as the subcutaneous
deposits of fat, which was also reduced significantly. Bone
mineral density was also decreased with symptoms of kyphosis
(Min et al., 2008). CHIP has also been found to be involved
in early neuronal development stages. The study conducted
by Yang et al. (2013) shows that CHIP regulates the level of
katanin-p60 protein, which is required for the proper axonal
growth in early developmental stages. CHIP antagonizes the
effects of a deubiquitylating enzyme, USP47, by ubiquitinating
and destabilizing katanin-p60, and hence presents an important
role in axonal growth (Yang et al., 2013). Another study showed
abnormal motor disturbances with altered phenotypic and
behavioral functions in CHIP heterozygous mice (McLaughlin
et al., 2012). CHIP may also have some indirect regulatory
roles over various neurodevelopmental processes through its
large number of substrates, where it regulates various proteins
which are directly involved in brain development processes. For
example, one of its substrates, PTEN is a key signaling molecule
that have direct role in various developmental processes
like neuronal differentiation and neurite growth (Li et al.,
2003; Hsia et al., 2014). The cellular level of PTEN is largely
regulated by its proteasomal degradation, governed by various
E3 ubiquitin ligases, including CHIP (Ahmed et al., 2012).
Cytoskeleton of large neurons are majorly built by cytoskeletal
proteins, neurofilaments. Evidence shows that CHIP has direct
involvement in proteasomal degradation of neurofilaments
medium subunit of 95 kDa, which are highly damaged and
decreased in the less understood mechanism of 2, 5-hexanedione
mediated neuropathology. Therefore, involvement of CHIP-
mediated proteasomal degradation presents a regulatory
mechanism to maintain the levels of neurofilament proteins
(Wang Q. et al., 2011; Dale and Garcia, 2012). Although these
studies indicate possibilities of CHIP involvement in various
developmental processes; a lack of function of which may
result in severe developmental abnormalities. These reports
give us some clues to further investigate its roles in more
details.
Involvement of CHIP in the regulation of aging processes is
also very crucial and yet to be established completely. Apart from
activation of HSF1, CHIP also affects the activity and stability
of the sirtuin family of proteins, which importantly regulate
DNA repair mechanisms and maintain cellular homeostasis,
by providing required genomic integrity. It was observed
that in mouse embryonic fibroblast and human embryonic
kidney cells, CHIP knockdown causes post-translational decay
of Sirtuin (SirT6) protein levels in the cells. Ubiquitination of
SirT6 at K170 position by CHIP E3 ubiquitin ligase stabilizes
the protein, which is rather degraded by some unknown E3
ubiquitin ligase. Such kind of positive regulation of SirT6 by
CHIP provides a novel example where these two arms of
DNA and protein quality maintenance systems cooperatively
regulate homeostasis and aging processes (Ronnebaum et al.,
2013). Exome sequencing analysis in a family affected with
ataxia, found the loss of function mutation in CHIP resulting
in hypogonadism and ataxia like symptoms. The reported
Thr346Met mutation resulted in Gordon Holmes Syndrome and
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other accelerated aging related changes which may probably
be a result of protein instability or impaired substrate binding
(Heimdal et al., 2014; Shi et al., 2014). Therefore, apart
from development, aging is another major area of research,
where detailed reports stating direct roles of CHIP are still
missing, which gives us an opportunity to dig out further, the
possibilities of CHIP being targeted as a candidate for anti-aging
strategies.
CHIP: IMPLICATIONS IN VARIOUS
DISEASES
Apart from the above described roles of CHIP in
neurodegeneration, development and aging, strong evidence
has indicated the importance of CHIP in diseases, such as
cancer, cardiac, muscular disorders, etc. A study in past
has elucidated the potential of CHIP as a biomarker and
therapeutic target in various human cancers (Sun et al.,
2014). The strategies have been adapted to target E1 enzymes,
chaperones, histone deacetylases, proteasomal subunits and
E3 ubiquitin ligases, like mouse double minute 2 homolog
(MDM2), anaphase-promoting complex (APC), etc., to treat
various types of cancers with varying success (Eldridge and
O’brien, 2010; Shen et al., 2013; Weathington and Mallampalli,
2014). As in renal cell carcinoma and gastric cancer, decreased
CHIP expression has shown potential to serve as a potent
biomarker of angiogenesis (Wang et al., 2013b; Sun et al.,
2014). Similarly, in esophageal squamous cell carcinoma
patients, elevated CHIP expression levels in metastatic lymph
node have shown a high prognostic value (Wen et al., 2013).
CHIP’s ability to downregulate ErbB2 makes it a potential
indicator for breast cancer patients’ survival (Jan et al., 2011).
Besides being extensively studied for prognostic ability,
CHIP has also been induced with the help of certain small
molecules.
Trehalose, a disaccharide, improves the deteriorating changes
taking place in patients with ataxia due to a genetic mutation
in STUB1/CHIP. Trehalose, apart from activation of autophagy,
also increases the levels of CHIP and Hsp70 (Casarejos et al.,
2014). Another molecule quercetin, a flavonoid present in
fruits and vegetables, is a chemopreventive agent in cancer;
shows its beneficiary effects by down regulating ErbB2 and
upregulating its E3 ubiquitin ligase CHIP (Jeong et al., 2008).
Another interesting example of using small natural molecule
is gambogic acid, a xanthonoid, obtained from tree Garcinia
hanburyi that inhibits the interaction of Hsp90 and mutant
p53 to make it available for CHIP-mediated proteasomal
degradation in cancer cells (Wang J. et al., 2011). Similarly,
curcumin has been shown to induce CHIP-ErbB2 interaction,
thereby reducing ErbB2 levels, a strategy shown to have an
enormous potential in controlling metastasis (Jung et al., 2007).
Besides these, a recent study also showed a protective effect
of CHIP against ER stress-mediated cell death in the central
nervous system, by preventing upregulation of p53 pathway and
regulating unfolded protein response pathways (Cabral Miranda
et al., 2015). Also, upregulating CHIP activity with Hsp90
inhibitors like 17-N-allylamino-17-demethoxygeldanamycin, for
anticancer therapy could be an effective strategy (Paul et al.,
2013).
Deubiquitinases (DUBs) are special class of proteases which
can release ubiquitin from substrate proteins by breaking the
peptide bonds in between substrate and ubiquitin molecules.
Regulating DUBs activities is assumed to have some possible
therapeutic benefits. Ataxin-3, one of the most studied DUB,
found to have a direct interaction with CHIP along with
an E2 enzyme Ube2W in degradation of its substrates. An
important mechanism of regulation of DUB ataxin-3 by its
ubiquitination is also present inside the cells. CHIP has shown
to have the capacity to ubiquitinate ataxin-3 and in turn may
have a regulatory effect on this neuroprotective DUB enzyme
(Scaglione et al., 2011; Tsou et al., 2013). A different therapeutic
strategy was proposed to enhance the efficacy of anticancer
drugs, through CHIP, by modulating CYP3A4 functioning
(Peer et al., 2011). CHIP also has a pivotal role in cardiac
disorders, where it provides cardioprotection by degrading
inducible cAMP early repressor in complex with extracellular
stress-regulated kinase 5 (Woo et al., 2010). All the above
described roles of CHIP, in various disorders elucidate its
significance for future research to develop advanced strategies
to control these pathological disorders. Although, CHIP is a
potential molecule for effectively targeting multiple cellular
targets involved in several diseases, still success in devising any
notable strategy to treat any of these diseases is not reported
so far. So, a precise focus on some key questions, which
are yet to be answered, must be given and more conceptual




Many years of research has established CHIP, as a unique
molecule, which has a large number of interacting partners. An
interaction network of such a wide variety of substrates enables
this E3 ligase enzyme to take part, directly or indirectly, in
an array of cellular functions including metabolism, signaling,
proliferation and apoptosis. The structure of CHIP, consisting
of both TPR and U-box domain, is also a crucial factor in
deciding its functional capabilities. Performing the roles of
co-chaperone and E3 ligase simultaneously needs enormous
molecular capabilities, and its advantageous structure provides
it an extra edge in performing these dual functions. It is still
a matter of investigation how exactly these decisions are being
made by CHIP, inside the cells. A major question yet to be
answered is, how CHIP, in combination with other chaperones
recognizes the abnormal and to be degraded substrates inside
the cytoplasm. Further work in this direction will indeed aid in
understanding the possible ways of identifying cellular proteins
on the basis of their structural and physiological features. Several
studies have been done to explore the methods of discriminating
the abnormal proteins from the healthy ones, whether they are
to be modified, modulated or degraded. But, a clear answer is
still far from our current understanding. Major focus of research
over CHIP has been given to its roles in signaling, apoptosis and
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cell proliferation. But, a line of evidence clearly indicates that
this molecule has equally important contribution in maintaining
the cellular homeostasis and providing protection from various
stresses, which are major factors causing protein aggregation and
related neurodegenerative diseases. Few possible developmental
and aging-related roles of CHIP has also been observed; still a lot
of research is needed to be done to understand the physiological
importance of CHIP in neurodevelopmental and aging processes.
KEY QUESTIONS AND FUTURE
PERSPECTIVES
Maintaining a healthy proteome is a prerequisite of a living
cell. To achieve this, cells are evolved with chaperone machinery
and quality control pathways that maintain proteins into proper
conformation and protect cells from toxicity generated in various
pathological conditions (Yerbury et al., 2016). CHIP represents
a protein which links all these pathways and machinery
together. It not only helps chaperones to fold proteins, but also
directs misfolded proteinaceous species for their proteasomal
or lysosomal degradation. Interestingly, CHIP also regulates
chaperones by ubiquitination and to more surprise, it also
has self-ubiquitination property, which makes it capable of
regulating its own turnover (Murata et al., 2001). Despite the
potential that CHIP and other E3 ubiquitin ligases have, as
therapeutic agents, more data is required, and further work is
needed to be done, to understand the extent of E3 ubiquitin
ligases in controlling various cellular processes. Chaperone-
independent role of CHIP is still needed to be fully established,
which can unveil its various other properties. How to achieve
specificity, in the case of CHIP, is another criterion that should
be worked upon, if this multifaceted ligase has to be used
for therapeutic benefits. Being a central molecule in various
processes, merely overexpressing it will also affect other pathways
and substrates that could prove this strategy detrimental in
place of being beneficial. So, besides looking for pathways
and substrates, properties and strategies, that could increase
specificity for intended substrate will undoubtedly open a new
area for treating diseases that are difficult to handle, with our
current treatment strategies.
Although, enough reports have been made to establish
protective roles of E3 ubiquitin ligases in various
neurodegenerative diseases, still no notable success has been
registered so far to treat these life-threatening neuronal
disorders. In one of our previous review articles, we have selected
few such E3 ligases which have shown cellular protection against
these pathological conditions (Upadhyay et al., 2015). CHIP,
with an array of protein quality control functions, including
regulation of chaperones and autophagic pathways, posits it
as one prominent candidate, which has a huge potential to be
targeted in the future therapeutic models of neurodegenerative
diseases. The ability of CHIP to interact with numerous proteins
and participation in multiple cellular pathways makes it one of
the most interesting E3 ubiquitin ligase. CHIP, with described
functions, bestows to be a possible future therapeutic target
which could be exploited by the drug industry in the future.
With such a significant contribution in cellular homeostasis,
CHIP needs further attention of the scientific community to
think and devise strategies to regulate multiple pathways of
cellular importance by using this molecule. Focus on specific
details and elaborated knowledge of underlying mechanisms will
allow us to use CHIP as a therapeutic molecule in future.
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